On November 7, 2018 Sysmex Corporation reported that actual financial results during the six months ended September 30, 2018, differed in some respects from the forecast announced on May 9, 2018 (Press release, Sysmex, NOV 7, 2018, View Source [SID1234530822]). In addition, Sysmex
has revised its financial forecast for the full fiscal year ending March 31, 2019. These differences are described below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. Differences between Actual and Forecast of Consolidated Financial Results for the Six Months Ended September 30, 2018 (April 1, 2018 to September 30, 2018)

Reasons for the Differences and Revision
On the consolidated sales front, in the first six months of the fiscal year ending March 31, 2019, sales in the Japan and EMEA regions were lower than previously forecast. As for profit, we worked to curtail selling, general and administrative expenses, but these reductions were unable to overcome the impact on profits of lower-than-expected sales. In addition, we recorded an exchange loss. As a result, operating profit, profit before tax and profit attributable to owners of the parent were lower than previously forecast.

Consequently, we have revised downward our forecast for the full fiscal year ending March 31, 2019, as we now expect sales, operating profit, profit before tax and profit attributable to owners of the parent to be below our previously forecast figures.

The foreign exchange assumptions used for calculating financial forecasts from the third quarter onward remain unchanged from our initial assumptions, at US$1.00 = ¥110 and €1 = ¥130.